Skip to main content
. 2013 Feb 26;6:107–118. doi: 10.2147/OTT.S30238

Table 6.

Platinum-sensitive recurrent EOC

Study Agents Number of patients RR PFS median OS median
OCEANS42 GC + bev 242 78.5% 12.4 months; 10.4 months
HR 0.484 (0.388–0.605) HR 0.534
P < 0.0001 (0.408–0.698)
GC + placebo 242 57.4% 8.4 months 7.4 months

Abbreviations: bev, bevacizumab; EOC, epithelial ovarian cancer; GC, gemcitabine and carboplatin; HR, hazard ratio; OCEANS, The Ovarian Cancer Education Awareness Network; OS, overall survival; PFS, progression-free survival; RR, relative risk.